Image

GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy

GRAViceptive NEGlect Treatment in Acute Stroke Using Targeted Cranial ELECTrotherapy

Recruiting
18-80 years
All
Phase 1/2

Powered by AI

Overview

We aim to determine if targeted high-definition transcranial direct current stimulation (HD-tDCS) can safely correct errors in visual verticality perception in patients after stroke affecting either hemisphere.

Description

This study explores a new approach to treat graviceptive neglect, a condition that affects balance and perception of uprightness, using a non-invasive brain stimulation technique called HD-tDCS (high-definition transcranial direct current stimulation). Using a phase I/II randomized sham-controlled double-blind parallel clinical trial design, we aim to analyze if HD-tDCS can safely help correct abnormal visual verticality perception in 28 people after stroke. We will also investigate the effects of our protocol on cerebrovascular response using transcranial Doppler and cortical activity using EEG. Neuroanatomical characteristics will be analyzed to establish the relationship between verticality perception error and the extent of temporo-parietal junction (TPJ) damage and, more broadly, the putative VV structural brain Network (VVN). Each participant will receive six HD-tDCS sessions of 2mA for 20 minutes in a central cathode montage applied over the contralesional TPJ. Patients will be randomized into two groups, with 50% receiving active stimulation and 50% receiving sham stimulation. The sham stimulation condition will consist of the same electrode placement, with a 2mA ramp-up over 30 seconds, followed by a 30-second ramp-down. Both groups will undergo 6 sessions, three times a day, for 2 days. The follow-up assessment will be performed 1 month after stimulation.

Eligibility

Inclusion Criteria:

  • Supratentorial ischemic stroke diagnosed by neuroimaging and clinical analysis;
  • Clinically stable (stable vital signs for 24 hours; no chest pain in the last 24 hours; no significant arrhythmia; no evidence of deep vein thrombosis);
  • Normal or corrected-to-normal vision;
  • No previous experience with HD-tDCS;
  • Ability to provide informed consent (patient or legal representative);
  • Ability to comply with the intervention and assessment schedule of the protocol.
  • Presence of visual verticality misperception.

Exclusion Criteria:

  • Migraine;
  • Pregnancy;
  • Pacemakers;
  • Seizures;
  • Claustrophobia;
  • Transient ischemic attack;
  • Other neurological disorders;
  • Psychiatric disorders;
  • Sensitive scalp or prior brain surgery;
  • Diagnosis of severe carotid atherosclerotic disease (stenosis ≥ 70%);
  • Presence of metal implants, cardiac pacemakers, or claustrophobia;
  • Diagnosis of COVID-19 or other infectious disease that requires isolation;
  • Uncontrolled medical problems, such as terminal cancer or kidney disease.
  • Left-handed or mixed-handed individuals as determined using the Edinburgh Handedness Inventory (Appendix 10);
  • Peripheral vestibular deficits observed using neuro-otological screening tests when the participant's clinical condition allows (head shake test, head thrust test, Dix-Hallpike, and Pagnini-McClure);
  • Prior musculoskeletal disorders affecting alignment and postural balance (e.g., moderate to severe scoliosis; torticollis);
  • Cognitive dysfunction outside normal limits on the Mini-Mental State Examination (score below 23);
  • Global or Wernicke's aphasia;

Study details
    Stroke

NCT06747676

University of Sao Paulo

4 September 2025

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.